Skip to main content

Saphris News

Actavis Receives FDA Approval of Saphris for Pediatric Patients with Bipolar I Disorder

DUBLIN, March 13, 2015 /PRNewswire/ – Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for Saphris...

FDA Medwatch Alert: Saphris (asenapine maleate): Drug Safety Communication: Serious Allergic Reactions

[Posted 09/01/2011] ISSUE: FDA notified healthcare professionals and patients that serious allergic reactions have been reported with the use of Saphris (asenapine maleate). The Contraindications,...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Bipolar Disorder, Schizophrenia

Saphris patient information at Drugs.com